Related Experiment Videos

[Apolipoprotein (a) phenotypes of patients with myocardial infarction]

Y Zhong1, J Li, J Wang

  • 1Department of Biochemistry, General Hospital of Nanjing Commend.

Insights

Apolipoprotein (a) phenotypes and Lp(a) levels differ in patients with cardiovascular and cerebrovascular diseases compared to healthy individuals. Specific apo(a) phenotypes, like B, S1, and S2, were more frequent in patients, indicating a potential link to disease risk.

Area of Science:

  • Biochemistry
  • Genetics
  • Cardiology
  • Neurology

Context:

  • Cardio-cerebrovascular diseases (CCVD) pose a significant global health burden.
  • Apolipoprotein (a) [apo(a)] is a key component of lipoprotein(a) [Lp(a)], a known risk factor for atherosclerosis.
  • Understanding apo(a) phenotypes and their association with CCVD is crucial for risk stratification.

Purpose:

  • To investigate the association between apo(a) phenotypes and Lp(a) serum concentrations in Chinese patients with myocardial infarction and stroke.
  • To compare the distribution of apo(a) phenotypes and Lp(a) levels between CCVD patients and healthy controls.

Summary:

  • This study analyzed apo(a) phenotypes in 69 myocardial infarction survivors, 56 stroke patients, and 190 healthy Chinese individuals.
  • A distinct distribution of apo(a) phenotypes was observed in CCVD patients compared to controls.
  • Specifically, phenotypes B, S1, and S2 were significantly more frequent in patients, and Lp(a) serum concentrations were higher in CCVD patients within the same single-band apo(a) phenotype.

Impact:

  • Findings suggest that specific apo(a) phenotypes may serve as potential biomarkers for increased risk of cardio-cerebrovascular diseases.
  • This research contributes to a deeper understanding of the genetic and molecular underpinnings of CCVD.
  • Further investigation into the role of apo(a) in atherogenesis could lead to novel therapeutic strategies.

Related Concept Videos